Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
DMVT-506
- Development stage
- Preclinical
- Lead developer
- Dermavant Sciences
- Modality
- Small Molecules
- Administration
- Topical
01
Overview
DMVT-506 is a next-generation small molecule aryl hydrocarbon receptor (AhR) agonist under development by Dermavant as a potential treatment for immunological and inflammatory diseases. It is designed to modulate the AhR pathway, which plays a role in immune regulation and inflammation. DMVT-506 has a similar pharmacologic profile to tapinarof (the active ingredient in VTAMA cream), but represents an advancement intended for broader or improved application. The drug is being explored with multiple potential routes of administration, though topical delivery is currently highlighted in available sources[1][3][5]. As of now, it remains in preclinical development.
02
Targets
AHR (Aryl hydrocarbon receptor)
Beyond the preview
Go deeper on DMVT-506.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on DMVT-506.